ADC Therapeutics(ADCT) - 2024 Q2 - Quarterly Report

Product Development and Pipeline - ADC Therapeutics aims to expand its ADC portfolio focusing on hematology and solid tumors, leveraging a validated technology platform and strategic partnerships [115]. - ZYNLONTA, the flagship product, received accelerated FDA approval for relapsed or refractory DLBCL, with ongoing international expansion efforts and clinical trials [116]. - In the LOTIS-7 trial, ZYNLONTA combined with bispecific antibodies showed promising anti-tumor activity with no dose-limiting toxicities observed in the dose escalation phase [119]. - Initial data from a Phase 2 trial of ZYNLONTA in relapsed/refractory MZL indicated a 86.7% complete response rate among evaluable patients, highlighting its potential in a high unmet need area [126]. - The solid tumor pipeline includes ADCs targeting NaPi2b and Claudin-6, currently in IND-enabling studies, with PSMA and ASCT2 candidates in drug selection stage expected to complete this year [129]. - The company is developing optimized ADCs targeting Claudin-6 and NaPi2b, with potential high impact in platinum-resistant ovarian cancer and non-small cell lung cancer [132]. - The company hosted a Research Investor Event to discuss its novel exatecan-based ADC platform, emphasizing its differentiated profile and therapeutic index [131]. Clinical Trials and Results - The LOTIS-7 trial is a global multicenter study evaluating ZYNLONTA in combination with bispecific antibodies, with ongoing enrollment in the dose expansion phase [122]. - As of April 2024, the LOTIS-7 trial reported that 88.8% of patients experienced Grade 3/4 adverse events, with manageable safety profiles observed [125]. - The company plans to pursue regulatory pathways for ZYNLONTA in MZL as trial results continue to be positive, aiming to address the high unmet medical need in this patient population [128]. Financial Performance - Product revenues, net, decreased to $17.0 million for the three months ended June 30, 2024, down$2.2 million or 11.3% from $19.2 million in the same period of 2023 [140]. - Total revenue, net, was$17.4 million for the three months ended June 30, 2024, a decrease of $1.9 million or 9.7$19.3 million in the same period of 2023 [138]. - License revenues and royalties increased significantly to $380 thousand for the three months ended June 30, 2024, compared to$86 thousand in the same period of 2023, representing a 341.9% increase [143]. - Net loss for the three months ended June 30, 2024, was $36.5 million, a decrease of$12.4 million or 25.3% from a net loss of $48.9 million in the same period of 2023 [138]. - Net loss per share, basic and diluted, improved to$(0.38) for the three months ended June 30, 2024, compared to $(0.60) in the same period of 2023, reflecting a 36.7$35.5 million for the six months ended June 30, 2024, down from $38.3 million in 2023, a decline of$2.8 million or 7.3% [172]. - Net loss for the six months ended June 30, 2024, was $83.2 million, compared to a net loss of$108.3 million in 2023, a reduction of $25.1 million or 23.2$34.9 million for the six months ended June 30, 2024, down from $38.2 million for the same period in 2023, representing an 8.6$24.3 million for the three months ended June 30, 2024, down $7.0 million or 22.5$31.3 million in the same period of 2023 [148]. - Research and development expenses totaled $50.0 million for the six months ended June 30, 2024, a decrease of 28.2$69.7 million for the same period in 2023 [179]. - Selling and marketing expenses decreased to $10.7 million for the three months ended June 30, 2024, down from$14.5 million in 2023, a reduction of $3.8 million or 26.0$10.2 million for the three months ended June 30, 2024, compared to $12.0 million in 2023, a decrease of$1.8 million or 14.7% [164]. - Research and development expenses for ZYNLONTA were $12.2 million for the three months ended June 30, 2024, down$4.4 million from $16.5 million in the same period of 2023 [149]. - Research and development expenses for ZYNLONTA were$27.1 million for the six months ended June 30, 2024, down from $35.8 million for the same period in 2023, a decrease of 24.0$22.1 million for the six months ended June 30, 2024, down 25.9% from $29.8 million for the same period in 2023 [189]. - General and administrative expenses decreased to$22.3 million for the six months ended June 30, 2024, from $27.5 million for the same period in 2023, a reduction of 19.0$105.0 million in gross proceeds, with net proceeds of approximately $97.4 million after transaction costs [134]. - The company recorded a net cash used in operating activities of$76.9 million for the six months ended June 30, 2024, compared to $50.4 million for the same period in 2023, an increase of$26.6 million [206]. - Net cash provided by financing activities was $99.1 million for the six months ended June 30, 2024, primarily from the completion of the 2024 Equity Offering [208]. - The company had cash and cash equivalents of$300.1 million as of June 30, 2024, sufficient to fund operations for at least the next twelve months [201]. - The company recorded an income tax expense of $(0.4) million for the six months ended June 30, 2024, compared to a benefit of$4.0 million for the same period in 2023 [199]. - The company had an accumulated deficit of $1,418.6 million as of June 30, 2024, with operations historically funded through equity offerings and debt financings [202]. Interest Income and Expense - Interest income increased to$3.3 million for the three months ended June 30, 2024, up from $2.4 million in the same period of 2023, an increase of$0.9 million [165]. - Interest expense rose to $12.7 million for the three months ended June 30, 2024, compared to$10.3 million in 2023, an increase of $2.4 million or 23.0$6.2 million for the six months ended June 30, 2024, up 36.4% from $4.5 million for the same period in 2023 [193]. - Interest expense rose to$25.2 million for the six months ended June 30, 2024, an increase of 22.2% from $20.6 million for the same period in 2023 [194].